-
News | 2025.03.26
Training the Physician-Scientists of Tomorrow: Institut Pasteur MD-PhD Program
In the face of global health crises and growing public health challenges, strengthening the links between scientific research (both fundamental and applied) and clinical practice has become essential. Recognizing this need, the Institut Pasteur has launched the MD-PhD program as part of its “Pasteur 2030” strategic plan, aiming to engage the Institute in training physician-scientists who can...
-
Document de presse | 2025.03.31
MOPEVACLAS vaccine candidate for Lassa fever enters clinical trials
After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an original vaccine platform known as MOPEVAC, which will strengthen the Institut Pasteur's pandemic preparedness initiatives. A Phase Ia clinical trial led by a research team at the Institut Pasteur is set to begin for the platform's first vaccine candidate, which targets Lassa fever...
-
News | 2017.09.15
Lyme disease – chipmunks may affect tick infection but the risk of transmission is more complex
Lyme disease is caused by bacteria transmitted by the bite of an infected tick of the Ixodes genus. Researchers from the Institut Pasteur have investigated tick infection when Siberian chipmunks are present, as these rodents are thought to be a reservoir for the bacteria. This pet, which was popular in the 1970s, was introduced to some forests where it now thrives, like in Sénart Forest, south-...
-
News | 2018.01.11
Frédéric Tangy, expert from the Institut Pasteur, talks about vaccines of today and tomorrow
In 2017, vaccinology expert Frédéric Tangy was recognized by the Institut Pasteur for his work on the Measles Platform and was elected as a member of the US National Academy of Inventors. As the Institut Pasteur enters its 130th year – it will be celebrating its 130th anniversary on November 14, 2018 – it seemed like a good opportunity to ask the scientist to tell us a little more about his...
-
Portrait | 2019.02.12
An Epidemiologist Faces Ebola in The Democratic Republic of the Congo
Ebola has battered the Democratic Republic of the Congo for many months, from the outbreak that ended in July 2018 to the epidemic currently raging. These are reminders that there is progress to be made in terms of controlling and understanding this deadly infectious disease. In 2018, during the epidemic in the north west of the country, Dr. Amber Kunkel, a scientist from the Institut Pasteur in...
-
News | 2020.04.28
COVID-19 pandemic: The Institut Pasteur International Network collective effort
To this day, SARS-CoV2, the virus responsible for COVID-19 pandemic, has been identified in more than 180 countries. It unfolded a once-in-a-century public health crisis, through his extensive impact on global economy directly caused by confinement measures. To confront these challenges, the 32 member institutes of the Institut Pasteur International Network (IPIN) are swinging into...
-
News | 2020.04.28
COVID-19 pandemic: The Institut Pasteur International Network collective effort
To this day, SARS-CoV2, the virus responsible for COVID-19 pandemic, has been identified in more than 180 countries. It unfolded a once-in-a-century public health crisis, through his extensive impact on global economy directly caused by confinement measures. To confront these challenges, the 32 member institutes of the Institut Pasteur International Network (IPIN) are swinging into...
-
Document de presse | 2021.01.25
COVID-19: progress update on the Institut Pasteur's scientific response and vaccine candidate research programs
Since early 2020, the Institut Pasteur has been engaged in research in several of its areas of scientific expertise, including virology, diagnostics, pathophysiology, epidemiology, modeling, therapeutic research and vaccine research. A number of research programs to find a vaccine for SARS-CoV-2, the virus responsible for the COVID-19 epidemic, are under way. In light of the intermediate results...
-
Document de presse | 2021.06.22
Drug repurposing to counter COVID-19: antiviral activity may be induced by phospholipidosis
Over the past 16 months and against the backdrop of the COVID-19 health crisis, thousands of drugs have been tested with a view to repurpose them to tackle SARS-CoV-2. Many of these drugs have demonstrated potential antiviral activity (23 compounds including hydroxychloroquine, azithromycin, amiodarone and 4 others tested in clinical trials). Given this high number of potential treatments, the...
-
News | 2023.07.10
HIV-AIDS: a virus master of evasion
Developing effective therapeutic vaccines requires knowing how to chemically recognize microbes, as well as exposing them to treatment. Able to mutate very quickly and to camouflage itself inside the cells it infects, the AIDS virus (or HIV) constitutes a challenge for researchers.